Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma

Lichenoid reactions are one of the many cutaneous immune-related adverse events seen with the use of immune checkpoint inhibitors, particularly anti-PD1 inhibitors. We present a rare care of severe lichen planopilaris secondary to pembrolizumab, with progression even after cessation of immunotherapy. It is important to recognise the significant long-term impact of these cutaneous adverse effects on patient's quality of life.

Automated summary

Lichenoid reactions can be a potential severe adverse effect of immune checkpoint inhibitors, with long-term impact on patient's quality of life.